Dr. Meindl is a biologist and received his doctorate from the University of Basel at Novartis. He began his career at Sympore GmbH in Tübingen, where he was involved in the development of novel pharmaceuticals in the field of inflammation and immunosuppression. From there he moved to SKM Oncology, where he worked in clinical research for oncology studies. He has been working for Labor LS for 20 years as head of various departments (biological assays, endotoxins, molecular biology, disinfectant testing, validation officer, LIMS project manager, R&D, implementation of new molecular methods). He is a member of the ECA Microbiology Board and the FAH Board.